On October 2, 2025,
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications,
announced the closing of its underwritten public offering of 7,475,000 shares of its common stock, which includes 975,000 shares sold pursuant to the underwriters’ full exercise of their option to purchase additional shares, at a price to the public of $10.00 per share. Enanta received approximately $74.8 million in gross proceeds, before deducting underwriting discounts and commissions and other offering expenses.
J.P. Morgan, Jefferies and Evercore ISI acted as joint book-running managers for the offering.
Foley Hoag attorneys Stacie Aarestad, Ryan Rourke Reed, Anna Snook, Caroline Samp and Emily Cain represented Enanta in connection with the offering.
